Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis.

ABSTRACT:

Background

It remains unknown what is the optimal front-line choice for advanced non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) fusion.

Methods

We conducted a systematic review and network meta-analysis of randomized phase III clinical trials comparing two or more treatments as the front-line setting for patients with advanced ALK-positive NSCLC.

Results

Nine phase III randomized clinical trials with 2367 patients were included. As to efficacy, lorlatinib had the most favorable progression-free survival [PFS; surface under the cumulative ranking curve (SUCRA) = 98.4%] in the first-line setting, with noticeable outcome benefits versus chemotherapy [hazard ratio (HR): 0.12; 95% confidence interval (CI): 0.08-0.19], crizotinib (HR: 0.28;

SUBMITTER: Wen Y 

PROVIDER: S-EPMC9403455 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature